Supplemental materials

# Protocol team structure

To oversee the implementation of this master protocol, a protocol team was formed including: Protocol co-chair(s)

* NIAID, Division of Clinical Research representatives
* INSIGHT University of Minnesota representatives
* INSIGHT International Coordinating Center representatives
* Representatives from collaborating trials networks
* Representative from ACTIV-2 protocol team
* Representatives from collaborating laboratory representatives
* Representatives from collaborating manufacturers of investigational agents
* Representatives from site investigators
* Study biostatisticians
* Community representative(s)

A core team consisting of the co-chair(s), ICC leaders, NIAID representatives, study statisticians, representatives from collaborating trials networks, and other representatives and the INSIGHT PI will also regularly convene to review study progress and address study conduct and administrative issues that arise.

# Randomization application

In order to facilitate randomizations to multiple possible agents, a flexible web-based randomization application was developed. The flexibility is accomplished with a database-driven approach pulling information from three tables: (i) randomisation table, which contains stratum specific schedules (as randomisation is stratified by pharmacy and disease severity) for one or multiple agents; (ii) drug table, which contains agent availability and allows stopping/restricting randomisation to selected agents, and information describing the agent, including number of doses of the agent available at the site study pharmacy; and (iii) constraint table, which contains contraindications and information used to modify inclusion/exclusion criteria. Randomisation assignments will be obtained in sequence from pre-generated schedules stratified by pharmacy and disease severity stratum. Allocation will be 1:1 Active:Placebo for one agent, 2:1:2:1 Active A:Placebo A:Active B:Placebo B for two agents (A and B), and so on. Using permuted blocks with k agents, every k placebo assignments will include one agent specific placebo assignment per agent, and every k active assignments will include one per agent. Using the mass-weighted urn scheme [6], the underlying Active:Placebo sequence is generated to ensure an approximate 1:1 balance for each active versus pooled placebo comparison within strata throughout the trial.

The application can also vary allocation according to stratum (i.e. pharmacy or disease severity). With 2 agents, allocation for the less severe stratum might be 2:1:2:1 as above but if agent B has not advanced to Stage-2 (and can therefore not recruit individuals with high disease severity), for the more severe stratum allocation would be 1:1 Active A: Placebo A. Furthermore, the application allows a limited number of sites to allocate patients 2:1:2:1: Active A:Placebo A:Active B:Placebo B or 1:1 Active B:Placebo B initially to obtain safety data for DSMB review for agent B while other sites randomize participants to only Active A; Placebo A until the safety review is complete.

# Pharmacy set-up options

A number of pharmacy options are available to participating sites.

1. A single study site pharmacy serving multiple clinical sites within a close geographical area (e.g. the same city). Local site’s clinical staff screen and randomise patient before ordering relevant SOC and placebo/agent from the study site pharmacy. SOC and placebo/agent are made up and the placebo/agent is blinded at the study site pharmacy before being distributed to the local site clinical staff for administration.
2. A single study site pharmacy serving multiple local site pharmacies within a close geographical area. Local site’s clinical staff screen and randomise patient before ordering relevant SOC and placebo/agent from the study site pharmacy. The study site pharmacy selects the appropriate number of vials of both SOC and placebo/agent, but do not prepare the study product, to be transported to the LSP. At the LSP, the SOC and placebo are made up and the placebo/agent is blinded before being distributed to clinical staff for administration.
3. A traditional pharmacy set-up where the study site pharmacy only serves a single clinical site

# Home/type of residence definitions

There are seven possible categories for classifying home in the TICO study. They are:

**Independent dwelling withOUT professional medical help -** Participant is living in a house, apartment, flat, condominium independently (regardless whether alone or with family or friends; also regardless of any paid help such as housekeeping service, maid, gardener etc.).

**Independent dwelling WITH professional medical help -** Participant is living in a house of any form, apartment, flat, or condominium but is requiring visiting professional medical help (e.g., visiting nurse, physiotherapist, or other home healthcare personnel meant to provide medical or rehabilitation care in the home)

**Community dwelling -** Participant is homeless, living on the streets or undomiciled, or may be living in a shelter or hotel (including hotel stay for quarantine purposes).

**Residential care facility -** These are non-skilled nursing facilities where care and services are provided to assist with activities of daily living. If the nature of the services can be safely and effectively performed by a trained nonmedical person, the services will be considered residential care. Examples include assisted living facility, group home, low-level care facility, or other nonmedical institutional setting.

**Other Healthcare facility -** Skilled nursing facility (nursing homes), acute inpatient rehabilitation facilities (acute rehab), or other healthcare facility that provides onsite medical care above a residential care facility but with a lower intensity than provided in hospitals.

**Long-term inpatient care hospital -** Long-term acute care hospital (LTACH), long-term care hospital. Note: These are hospitals/facilities meant to provide longer term (typically >20-30 days) of acute-care services after discharge from the short-term acute care hospital. Services requiring this level of care may include mechanical ventilation, intensive wound care, intensive pain management. LTACHs are hospitals that specialize in the treatment of patients with serious medical conditions that require care on an ongoing basis but no longer require intensive care or extensive diagnostic procedures.

**Short-term acute care hospital -** Short-term acute care hospital (similar to the index/enrolling hospital). Most acute care hospitals fall into this category, regardless of the duration of hospital admission.

# Stage-1 sample size selection

The following assumptions were made in estimating the required sample size for Stage-1, considering the marginal tests for each outcome separately.

1. The primary analysis will be intention-to-treat.
2. A proportional odds model with indicators for the investigational agent group and baseline severity of illness as defined by the ordinal outcome will be used to estimate the odds ratio (OR). The model will be stratified by study site pharmacy.
3. Type 1 error = 0.30 (1-sided) and power = 0.95.
4. The clinical status (% distribution for each pulmonary+ category) of participants in the placebo group at Day 5 is assumed as shown in the 3rd column in Supplemental Table 2. Since both randomized treatment groups will receive remdesivir as SOC (unless contraindicated), these percentages were estimated using Day 5 data from the ACTT1 trial for a subgroup of patients similar to the intended participants of this trial who were randomized to remdesivir.
5. We targeted an OR (active/placebo) of 1.60 for a more favourable outcome. This corresponds to the % distribution of the clinical status of participants in the investigational agent group at Day 5 shown in the 2nd column in Supplemental Table 2. For example, the percentage of participants in the 2 most favourable categories would be increased to 56.7% in the group receiving the investigational agent from 45.0% in the placebo group (a 11.7% increase). Conversely, the percentage of participants in the 4 most severe categories would decrease to 22.7% from 32.0% in the placebo group. The same proportional improvement was assumed across the ordinal scale.
6. Based on the category percentages in Supplemental Table 2, the estimated Stage-1 sample size with a single comparison between an investigational treatment and placebo is 293. This was increased to 300 to allow for some missing data at Day 5.

# Stage-2 Sample Size selection

The following assumptions were made in estimating the required sample size for Stage-2.

1. The primary analysis will be intention to treat. Gray’s test with rho=0 will be used [1], with stratification by disease severity at entry for comparing each investigational agent to control for the primary endpoint of time to sustained recovery. Gray’s test with rho=0 is the analogue of the log-rank test in the presence of competing risks; it is used here to account for the competing risk of death when analysing time to sustained recovery.
2. Type 1 error will be set at 0.025 (1-sided). This type 1 error will not be adjusted for the number of investigational agents being compared with placebo as each of the agents is expected to impact the primary endpoint through different mechanisms. If this is not the case, a type 1 error adjustment may be considered.
3. Power is set at 90% to detect a 25% increase in the rate of sustained recovery for the investigational treatment compared to placebo. This moderate efficacy is assumed considering the findings from ACTT1 and the percentage of patients in each baseline risk category of the ordinal outcome used in Stage-1. Based on the results from ACTT-1 [2], we expect approximately 50% of patients enrolled in Stage-2 to be in the more severe strata (5 and 6 in the ordinal categories shown in Supplemental Table 2). However, all patients who are enrolled in Stage-1 are in the less severe strata at entry (categories 3 and 4 in Supplemental Table 2). These patients will also be part of the primary analysis. Thus, we assume that 40% of patients in the final analysis will be in the more severe strata; mortality is expected to be higher for patients in the more severe strata. Among surviving patients, we assume most will have met the criteria for sustained recovery.
4. With these assumptions for type 1 and type 2 error and a sustained recovery rate ratio of 1.25 for the investigational agent versus control, 843 sustained recoveries are needed [3, 4].
5. Given the duration of follow-up, we estimate that the sample size is slightly larger than the number of recoveries (i.e., we expect a low rate of loss-to-follow-up or deaths). For 2 groups, we assume that the sample size is approximately 20% higher than the number of recoveries, to account for deaths, a small number of withdrawals of consent, and a small number of patients remaining in the hospital at Day 90. Total sample size for 2 groups is approximately 1,000 (500 per group). If 2 or 3 investigational treatments reach the end of Stage-2, sample size estimates are 1,500 and 2,000, respectively.
6. In order to observe 843 sustained recoveries among 1000 participants, and assuming 3% withdrawal of consent, at least 87% of participants (pooled across the two treatment arms) would have to achieve sustained recovery by Day 90. Assuming a recovery rate ratio of 1.25, this corresponds to 89.9% with sustained recovery among those randomized to the investigational agent, compared with 84.1% in the control group.

# Statistical Analyses

## Stage 2 Primary Analysis, Time to Sustained Recovery

The evaluation for the primary efficacy outcome for stage 2 of the Phase III trial, time to sustained recovery, will be based on Gray’s test with rho=0. The test will compare the investigational agent versus the control group by intention to treat, and will be stratified by disease severity at entry and study site pharmacy. Gray’s test compares the cumulative incidence functions for *sustained recovery* between the treatment groups, taking into account the ”competing risk” of death in analysing *sustained recovery*. Gray’s test with rho=0 is the analogue of the log-rank test in the presence of competing risks. Cumulative incidence functions for *sustained recovery* will be estimated by treatment group using the Aalen-Johansen estimator, and the recovery rate ratio (RRR) (investigational agent versus control) for *sustained recovery* will be estimated using the Fine-Gray method, stratified by disease severity at entry and study site pharmacy; the RRR will be estimated as a point estimate with a 95% CI. The Aalen-Johansen estimator for cumulative incidence functions is the analogue of the Kaplan-Meier estimator in the presence of competing risks. The Fine-Gray method is the competing risks equivalent of Cox proportional hazards models; the RRR compares the cumulative incidence rates of *sustained recovery* between the study arms, and is a sub-distribution hazards ratio. Analyses for the *sustained recovery* endpoint require methods that take into account the competing risk of death, as participants may die before ever achieving *sustained recovery*. The “sustained recovery” outcome requires knowledge of a participant’s residence status for at least 14 days after arriving “home”; since all participants are hospitalized at study entry, it takes at least 15 days to attain this outcome.

## Additional planned analyses

Several other secondary efficacy outcomes will also be investigated. The randomized treatment groups (investigational agent versus control) will be compared by intention to treat. The models will include an indicator for treatment group and stratify by study site pharmacy and disease severity at study entry as appropriate.

Mortality is a key secondary outcome; time to death will be compared between the investigational agent versus control using a log-rank test, stratified by disease severity and study site pharmacy; the hazard ratio will be estimated using a stratified Cox proportional hazards model, and the proportion of participants who died by fixed time points (for example, Day 28 or Day 90) will be estimated using Kaplan-Meier estimates. Additionally, to supplement the separate analyses of *time to sustained recovery* and *time to death*, the two endpoints will be analyzed jointly using the “win ratio” method[5] for the composite outcome of time to recovery or death. At a given time point (Day 90), the win ratio statistic ranks participants’ outcomes into three ordered categories, death, alive but not achieved sustained recovery, alive and achieved sustained recovery, and ties are broken by time since randomization. Matching on baseline disease severity will be used to estimate the win ratio statistic. This combination of time to sustained recovery and time to death is also a key secondary analysis.

Time from study entry to discharge from the hospital admission during which randomization took place will be analyzed using the same methods as described for time to sustained recovery, which take into account the competing risk of death.

Both ordinal outcomes used in Stage-1 will be assessed at Days 1 through 7; the pulmonary ordinal outcome will also be assessed at Days 14 and 28 and tests for differences between study arms will be conducted using proportional odds models.

# Supplemental tables

Supplemental Table Safety Data Collection Schedule

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | Infusion +2 hrs | Days 0-7 | Day 14 | Day 28 | Day 90 |
| Infusion-related reactions and symptoms | X |  |  |  |  |
| Incident grade 3 and 4 clinical AEs |  |  | X1 | X1 |  |
| Clinical AEs of any grade severity | X | X | X2 | X2 |  |
| Targeted laboratory abnormalities of any grade |  | X  (Day 5) |  |  |  |
| Serious AEs  (including those reported as part of the pulmonary and pulmonary+ ordinal outcomes) | Collected through Day 90 | | | | |
| Unanticipated problems | Collected through Day 90 | | | | |
| Any serious adverse event related to study intervention | Collected through Day 90 | | | | |

1. All grade 3 and 4 events since previous visit
2. All grade 1 and 2 events on the day of the visit only

Supplemental Table Hypothesized percentage of participants in each category on Day 5 in the investigational agent and placebo groups based on aforementioned assumptions.

|  |  |  |
| --- | --- | --- |
| **Pulmonary+ Category** | **Investigational Agent + SOC** | **Placebo + SOC** |
| 1. No limiting symptoms due to COVID-19 | 3.2 | 2.0 |
| 2. Limiting symptoms due to COVID-19 | 53.5 | 43.0 |
| 3. Moderate end-organ dysfunction | 20.6 | 23.0 |
| 4. Serious end-organ dysfunction | 12.8 | 17.0 |
| 5. Life-threatening end-organ dysfunction | 5.0 | 7.3 |
| 6. End-organ failure | 4.5 | 7.0 |
| 7. Death | 0.4 | 0.7 |
| Total | 100.0 | 100.0 |

Supplemental Table 3 Participating Clinical Sites

|  |  |  |
| --- | --- | --- |
| **INSIGHT Copenhagen ICC**  CHIP Centre of Excellence for Health, Immunity, and Infections, Department of Infectious Diseases, Rigshospitalet, Copenhagen, Denmark | | |
| **Site Name** | **City** | **Country** |
| University Hospital Zurich | Zurich | Switzerland |
| Unité VIH/SIDA Genèva | Geneva | Switzerland |
| Johann Wolfgang Goethe Univ. Ho sp., Infektionsambulanz CRS | Frankfurt | Germany |
| Universitätsklinik Köln | Cologne | Germany |
| Medizinische Universitätsklinik - Bonn, Immunologische Ambulanz CRS | Bonn | Germany |
| Klinikum der Universität München | Munich | Germany |
| Universitätsklinikum Düsseldorf | Duesseldorf | Germany |
| Universitätsklinikum Regensburg | Regensburg | Germany |
| Universitätsklinikum Hamburg-Eppendorf | Hamburg | Germany |
| Hospital Santa Maria | Lisbon | Portugal |
| Hvidovre University Hospital, Department of Infectious Diseases | Hvidovre | Denmark |
| Aarhus Universitetshospital, Skejby | Aarhus | Denmark |
| Odense University Hospital | Odense | Denmark |
| Aalborg Hospital | Aalborg | Denmark |
| Rigshspitalet, Department of Infectious Diseases | Copenhagen | Denmark |
| Nordsjællands Hospital, Hillerød | Hillerod | Denmark |
| Zealand University Hospital Roskilde | Roskilde | Denmark |
| Kolding Sygehus | Kolding | Denmark |
| Herlev-Gentofte Hospital | Hellerup | Denmark |
| Bispebjerg Hospital | Copenhagen | Denmark |
| Karolinska University Hospital | Stockholm | Sweden |
| Wojewodzki Szpital Zakazny | Warsaw | Poland |
| Hospital General Universitario Gregorio Marañón | Madrid | Spain |
| Hospital Universitari Germans Trias i Pujol | Badalona | Spain |
| Hospital Clínic de Barcelona | Barcelona | Spain |
| Hospital Universitario La Paz | Madrid | Spain |
| Hospital Clínico San Carlos | Madrid | Spain |
| Hospital del Mar | Barcelona | Spain |
| Hospital Universitari Vall d'Hebron | Barcelona | Spain |
| Hospital Universitario de Bellvitge | Hospitalet de Llobregat | Spain |
| AIDS and Clinical Immunology Research Center | Tbilisi | Georgia |
| Karolinska University Hospital | Stockholm | Sweden |
| **INSIGHT London ICC**  Medical Research Council Clinical Trials Unit at UCL, University College London, London, UK | | |
| **Site Name** | **City** | **Country** |
| Hôpital Saint-Louis | Paris | France |
| Groupe Hospitalier Sud Île de France | Melun | France |
| Hopital Lariboisière | Paris | France |
| Ospedale San Raffaele S.r.l. | Milan | Italy |
| L. Sacco Hospital-Institue of Infectious and Tropical Diseases | Milan | Italy |
| INMI Lazzaro Spallanzani IRCSS | Rome | Italy |
| Bergamo Hospital | Bergamo | Italy |
| Royal Sussex County Hospital | Brighton | United Kingdom |
| Royal Free Hospital | London | United Kingdom |
| Royal Victoria Infirmary | Newcastle upon Tyne | United Kingdom |
| Guy's & St. Thomas' NHS Foundation Trust | London | United Kingdom |
| Churchill Hospital | Oxford | United Kingdom |
| St James's University Hospital | Leeds | United Kingdom |
| Bradford Teaching Hospitals | Bradford | United Kingdom |
| MRC/UVRI Research Unit on AIDS | Entebbe | Uganda |
| Joint Clinical Research Center (JCRC) | Kampala | Uganda |
| Gulu Regional Referral Hospital | Gulu | Uganda |
| Mulago Hospital Complex | Kampala | Uganda |
| Lira Regional Referral Hospital | Lira | Uganda |
| Masaka Regional Referral Hospital | Masaka | Uganda |
| CISPOC | Maputo | Mozambique |
| Attikon University General Hospital | Athens | Greece |
| 1st Respiratory Medicine Dept, Athens University Medical School | Athens | Greece |
| AHEPA University Hospital | Thessaloniki | Greece |
| Dept of Critical Care and Pulmonary Medicine, Evangelismos General Hospital | Athens | Greece |
| Democritus University of Thrace | Alexandroupoli | Greece |
| 3rd Dept of Medicine, Medical School, NKUA | Athens | Greece |
| **INSIGHT Sydney ICC**  The Kirby Institute, University of New South Wales, Sydney, Australia | | |
| **Site Name** | **City** | **Country** |
| Hospital General de Agudos JM Ramos Mejia | Buenos Aires | Argentina |
| CEMIC | Buenos Aires | Argentina |
| Instituto Médico Platense | La Plata | Argentina |
| Fundación Arriarán | Santiago | Chile |
| St. Vincent's Hospital, Sydney | Sydney | Australia |
| Westmead Hospital | Sydney | Australia |
| NCGM | Tokyo | Japan |
| Fujita Health University Hospital | Toyoake | Japan |
| Tokyo Shinagawa Hospital | Tokyo | Japan |
| Tan Tock Seng Hospital | Singapore | Singapore |
| Chennai Antiviral Research and Treatment Clinical Research Site | Chennai | India |
| Institute of Human Virology-Nigeria (IHVN) | Abuja | Nigeria |
| Chulalongkorn University and The HIV-NAT | Pathumwan | Thailand |
| Bamrasnaradura Infections Diseases Institute | Nonthaburi | Thailand |
| Tel Aviv Sourasky Medical Center | Tel Aviv | Israel |
| Rambam Medical Center | Haifa | Israel |
| **INSIGHT Washington ICC**  Veterans Affairs Medical Center and George Washington University, Washington, DC, USA. | | |
| **Site Name** | **City** | **Country** |
| Lincoln Medical Center | Bronx | United States |
| Our Lady of the Lake Regional Medical Center | Baton Rouge | United States |
| University of Illinois at Chicago | Chicago | United States |
| Washington DC VA Medical Center | Washington | United States |
| Henry Ford Health System | Detroit | United States |
| Denver Public Health | Denver | United States |
| Cooper University Hospital | Camden | United States |
| Yale University School of Medicine | New Haven | United States |
| Triple O Research Institute | West Palm Beach | United States |
| Hennepin Healthcare Research Institute/HCMC | Minneapolis | United States |
| NJMS Adult Clinical Research Center | Newark | United States |
| Maimonides Medical Center | Brooklyn | United States |
| Medical College of Wisconsin, Inc. | Milwaukee | United States |
| Lundquist Institute for Biomedical Innovation | Torrance | United States |
| Georgetown University | Washington | United States |
| West Los Angeles VA Medical Center | Los Angeles | United States |
| San Francisco VAMC | San Francisco | United States |
| Miami VAMC | Miami | United States |
| Bay Pines VAMC | Bay Pines | United States |
| Palo Alto VAMC | Palo Alto | United States |
| Houston VAMC | Houston | United States |
| Minneapolis VA Health Care System | Minneapolis | United States |
| West Haven VA Medical Center | West Haven | United States |
| Southern Arizona VA Healthcare System | Tucson | United States |
| Aurora VAMC | Aurora | United States |
| North Florida/South Georgia Veterans Health Sysem | Gainesville | United States |
| Edward Hines VA Hospital | Hines | United States |
| VA Southern Nevada Healthcare System | Las Vegas | United States |
| Salem VA Medical Center | Salem | United States |
| Ralph H. Johnson VA Medical Center | Charleston | United States |
| VA San Diego Healthcare System | San Diego | United States |
| VA Loma Linda Healthcare System | Loma Linda | United States |
| CJ Zablocki VA Med Center | Milwaukee | United States |
| Oklahoma City VA Health Care System | Oklahoma City | United States |
| VA Pittsburgh | Pittsburgh | United States |
| Richard L. Roudebush VA Medical Center | Indianapolis | United States |
| VA TVHS Nashville Campus | Nashville | United States |
| Sacramento VA Medical Center | Mather | United States |
| Portland VA Health Care System | Portland | United States |
| UT Southwestern Medical Center | Dallas | United States |
| Case Western Reserve University | Cleveland | United States |
| M Health Fairview Bethesda Hospital | Saint Paul | United States |
| Instituto de Infectologia Emílio Ribas - IIER | Sao Paulo | Brazil |
| Center for Infectious Diseases at the UFES | Vitoria | Brazil |
| Complexo Hospitalar Professor Edgard Santos | Salvador | Brazil |
| Socios En Salud Sucursal Peru | Lima | Peru |
| Hospital Nacional Hipolito Unanue | El Agustino | Peru |
| Nutrición | Mexico City | Mexico |
| INER | Mexico City | Mexico |
| GEA | Mexico City | Mexico |
| **PETAL Network** | | |
| **Site Name** | **Site City** | **Country** |
|  |  |  |
| Baystate Medical Center | Springfield | United States |
| Maine Medical Center | Portland | United States |
| U. Florida, Health Science Center & Shands | Gainesville | United States |
| Beth Israel Deaconess Medical Center | Boston | United States |
| Massachusetts General Hospital | Boston | United States |
| University of Mississippi Medical Center | Jackson | United States |
| UCSF San Francisco | San Francisco | United States |
| Ronald Reagan UCLA Medical Center | Los Angeles | United States |
| Stanford University Hospital & Clinics | Stanford | United States |
| UC Davis | Davis | United States |
| UCSF Fresno | Fresno | United States |
| University of Texas Health Science Center | Houston | United States |
| UCSF Medical Center at Mount Zion | San Francisco | United States |
| University of Colorado Hospital | Aurora | United States |
| National Jewish Health | St. Joseph Hospital | Denver | United States |
| University of Michigan Medical Center | Ann Arbor | United States |
| Montefiore Medical Center Moses Hospital | Bronx | United States |
| Montefiore North | New York | United States |
| Montefiore Weiler | New York | United States |
| Banner University Medical Center Tucson | Tucson | United States |
| Cleveland Clinic Foundation | Cleveland | United States |
| University of Cincinnati Medical Center | Cincinnati | United States |
| Cleveland Clinic Fairview Campus | Cleveland | United States |
| Cleveland Clinic Marymount Campus | Cleveland | United States |
| Harborview Medical Center | Seattle | United States |
| Cedars-Sinai Medical Center | Los Angeles | United States |
| Oregon Health and Science University | Portland | United States |
| Swedish Hospital Cherry Hill | Seattle | United States |
| Swedish Hospital First Hill | Seattle | United States |
| University of Washington Medical Center | Seattle | United States |
| UPMC Presbyterian | Pittsburgh | United States |
| UPMC Magee | Pittsburgh | United States |
| UPMC Mercy | Pittsburgh | United States |
| UPMC Shadyside | Pittsburgh | United States |
| Wake Forest Baptist Health | Winston-Salem | United States |
| Medical University of South Carolina | Charleston | United States |
| University of Kentucky | Lexington | United States |
| Virginia Commonwealth University Health System | Richmond | United States |
| Intermountain Medical Center | Murray | United States |
| University of Utah Hospital | Salt Lake City | United States |
| Utah Valley Regional Medical Center | Provo | United States |
| LDS Hospital | Salt Lake City | United States |
| Vanderbilt University Medical Center | Nashville | United States |
| University Medical Center | New Orleans | United States |
| **CTSN Trials Network** | | |
| **Site Name** | **City** | **Country** |
| Allegheny General Hospital | Pittsburgh | United States |
| Baylor College of Medicine | Houston | United States |
| Baylor, Scott and White Health | Dallas | United States |
| Cedars-Sinai Medical Center | Los Angeles | United States |
| CHI St. Vincent, Arkansas | Little Rock | United States |
| Duke University Hospital | Durham | United States |
| East Carolina Heart Institute | Greenville | United States |
| Emory University | Atlanta | United States |
| Inova Heart & Vascular Institute | Falls Church | United States |
| Lutheran Medical Group | Fort Wayne | United States |
| MH Mission Hospital | Asheville | United States |
| Mount Sinai Medical Center | New York | United States |
| New York University Langone Health | New York | United States |
| Northwell Health | Manhasset | United States |
| Ochsner Clinic | New Orleans | United States |
| Piedmont Healthcare | Atlanta | United States |
| Texas Heart Institute | Houston | United States |
| University of Louisville | Louisville | United States |
| University of Maryland | Baltimore | United States |
| University of Southern California | Los Angeles | United States |
| University of Virginia Health Systems | Charlottesville | United States |
| WakeMed Heart Center | Raleigh | United States |
| West Virginia University | Morgantown | United States |
| Dartmouth-Hitchcock Medical Center | Lebanon | United States |
| Hôpital Laval | Quebec | Canada |